70 related articles for article (PubMed ID: 16814355)
1. A chimeric tetravalent dengue DNA vaccine elicits neutralizing antibody to all four virus serotypes in rhesus macaques.
Raviprakash K; Apt D; Brinkman A; Skinner C; Yang S; Dawes G; Ewing D; Wu SJ; Bass S; Punnonen J; Porter K
Virology; 2006 Sep; 353(1):166-73. PubMed ID: 16814355
[TBL] [Abstract][Full Text] [Related]
2. Induction of neutralization antibodies in mice by Dengue-2 envelope DNA vaccines.
Pérez-Vélez ME; García-Nieves T; Colón-Sánchez C; Martínez I
P R Health Sci J; 2009 Sep; 28(3):239-50. PubMed ID: 19715116
[TBL] [Abstract][Full Text] [Related]
3. Evolution and evolvability of proteins in the laboratory.
Deem MW
Proc Natl Acad Sci U S A; 2004 Mar; 101(12):3997-8. PubMed ID: 15024102
[No Abstract] [Full Text] [Related]
4. Preparedness for the Dengue Epidemic: Vaccine as a Viable Approach.
Zeyaullah M; Muzammil K; AlShahrani AM; Khan N; Ahmad I; Alam MS; Ahmad R; Khan WH
Vaccines (Basel); 2022 Nov; 10(11):. PubMed ID: 36423035
[TBL] [Abstract][Full Text] [Related]
5. Potential Role of Flavivirus NS2B-NS3 Proteases in Viral Pathogenesis and Anti-flavivirus Drug Discovery Employing Animal Cells and Models: A Review.
Wahaab A; Mustafa BE; Hameed M; Stevenson NJ; Anwar MN; Liu K; Wei J; Qiu Y; Ma Z
Viruses; 2021 Dec; 14(1):. PubMed ID: 35062249
[TBL] [Abstract][Full Text] [Related]
6. Dengue Virus and Vaccines: How Can DNA Immunization Contribute to This Challenge?
Alves AMB; Costa SM; Pinto PBA
Front Med Technol; 2021; 3():640964. PubMed ID: 35047911
[TBL] [Abstract][Full Text] [Related]
7. Mammalian animal models for dengue virus infection: a recent overview.
Kayesh MEH; Tsukiyama-Kohara K
Arch Virol; 2022 Jan; 167(1):31-44. PubMed ID: 34761286
[TBL] [Abstract][Full Text] [Related]
8. Anti-dengue Vaccines: From Development to Clinical Trials.
Pinheiro-Michelsen JR; Souza RDSO; Santana IVR; da Silva PS; Mendez EC; Luiz WB; Amorim JH
Front Immunol; 2020; 11():1252. PubMed ID: 32655561
[No Abstract] [Full Text] [Related]
9. Vaccination With a Single Consensus Envelope Protein Ectodomain Sequence Administered in a Heterologous Regimen Induces Tetravalent Immune Responses and Protection Against Dengue Viruses in Mice.
Wang R; Zheng X; Sun J; Feng K; Gao N; Fan D; Chen H; Jin X; An J
Front Microbiol; 2019; 10():1113. PubMed ID: 31134046
[TBL] [Abstract][Full Text] [Related]
10. Vaccines licensed and in clinical trials for the prevention of dengue.
Torresi J; Ebert G; Pellegrini M
Hum Vaccin Immunother; 2017 May; 13(5):1059-1072. PubMed ID: 28281864
[TBL] [Abstract][Full Text] [Related]
11. Multi-walled carbon nanotubes increase antibody-producing B cells in mice immunized with a tetravalent vaccine candidate for dengue virus.
Calegari LP; Dias RS; de Oliveira MD; Pessoa CR; de Oliveira AS; Oliveira AF; da Silva CC; Fonseca FG; Versiani AF; De Paula SO
J Nanobiotechnology; 2016 Jul; 14(1):61. PubMed ID: 27465605
[TBL] [Abstract][Full Text] [Related]
12. Production of a Recombinant Dengue Virus 2 NS5 Protein and Potential Use as a Vaccine Antigen.
Alves RPDS; Pereira LR; Fabris DLN; Salvador FS; Santos RA; Zanotto PMA; Romano CM; Amorim JH; Ferreira LCS
Clin Vaccine Immunol; 2016 Jun; 23(6):460-469. PubMed ID: 27030586
[TBL] [Abstract][Full Text] [Related]
13. Dengue E Protein Domain III-Based DNA Immunisation Induces Strong Antibody Responses to All Four Viral Serotypes.
Poggianella M; Slon Campos JL; Chan KR; Tan HC; Bestagno M; Ooi EE; Burrone OR
PLoS Negl Trop Dis; 2015; 9(7):e0003947. PubMed ID: 26218926
[TBL] [Abstract][Full Text] [Related]
14. Construction and Immunogenicity Evaluation of Recombinant Influenza A Viruses Containing Chimeric Hemagglutinin Genes Derived from Genetically Divergent Influenza A H1N1 Subtype Viruses.
McCormick K; Jiang Z; Zhu L; Lawson SR; Langenhorst R; Ransburgh R; Brunick C; Tracy MC; Hurtig HR; Mabee LM; Mingo M; Li Y; Webby RJ; Huber VC; Fang Y
PLoS One; 2015; 10(6):e0127649. PubMed ID: 26061265
[TBL] [Abstract][Full Text] [Related]
15. Utility, limitations, and future of non-human primates for dengue research and vaccine development.
Sariol CA; White LJ
Front Immunol; 2014; 5():452. PubMed ID: 25309540
[TBL] [Abstract][Full Text] [Related]
16. Mouse models to study dengue virus immunology and pathogenesis.
Zellweger RM; Shresta S
Front Immunol; 2014; 5():151. PubMed ID: 24782859
[TBL] [Abstract][Full Text] [Related]
17. Latest developments and future directions in dengue vaccines.
Thisyakorn U; Thisyakorn C
Ther Adv Vaccines; 2014 Jan; 2(1):3-9. PubMed ID: 24757522
[TBL] [Abstract][Full Text] [Related]
18. Viral kinetics of primary dengue virus infection in non-human primates: a systematic review and individual pooled analysis.
Althouse BM; Durbin AP; Hanley KA; Halstead SB; Weaver SC; Cummings DA
Virology; 2014 Mar; 452-453():237-46. PubMed ID: 24606701
[TBL] [Abstract][Full Text] [Related]
19. Dengue viruses - an overview.
Bäck AT; Lundkvist A
Infect Ecol Epidemiol; 2013 Aug; 3():. PubMed ID: 24003364
[TBL] [Abstract][Full Text] [Related]
20. Dengue virus photo-inactivated in presence of 1,5-iodonaphthylazide (INA) or AMT, a psoralen compound (4'-aminomethyl-trioxsalen) is highly immunogenic in mice.
Raviprakash K; Sun P; Raviv Y; Luke T; Martin N; Kochel T
Hum Vaccin Immunother; 2013 Nov; 9(11):2336-41. PubMed ID: 23835446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
